62 results about "Prothrombase" patented technology

The invention relates to a starch composite hemostatic dressing of mesoporous silica microspheres, which adopts a sol-gel method and uses a three-block copolymer pluronic as a template agent to synthesize mesoporous silica microspheres with a pore diameter of about 5 nm. It is compounded with starch to prepare a mesoporous silicon oxide microsphere / starch composite hemostatic dressing, and the hemostatic performance of the composite material is observed through animal experiments. The mesoporous silica microsphere / starch composite material not only has strong water absorption performance, but also has obvious in vitro coagulation performance, which can significantly shorten the partial thromboplastin time and prothrombin time. The mesoporous silica microsphere / starch composite material can prevent the bleeding of the rabbit's back skin and liver injury and shorten the bleeding time, and has obvious hemostatic effect.

The invention relates to a preparation process of a human prothrombin compound, belonging to the field of biological pharmacy. The preparation process comprises the following steps of: absorbing blood plasma, washing, eluting and clarifying by filtration; inactivating viruses by using the S / D (Solvent / Detergent) method; purifying by absorption; subpackaging; freeze-drying; and inactivating viruses by the dry heat method. The human prothrombin compound is directly absorbed from blood plasma by using gel, only the gel chromatography technology is used in the entire extraction process, so that the production steps are simplified, the pollution of various factors on the production process of the product is reduced, meanwhile, the yield of the product is increased by 25-30%. In addition, the S / D method is used for removing lipid-enveloped viruses and the dry heat method is used for removing non lipid-enveloped viruses in the production process, and the safety of clinic medication is obviously increased through the two virus inactivation steps.

Methods and apparatus are disclosed for determining new anticoagulant therapy factors for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. The inventive methods and apparatus provide an International Normalization Ratio (INR) based on a coagulation reaction with a blood sample of a living being. Embodiments include methods and apparatus for determining an anticoagulant therapy factor without requiring use of a mean normal prothrombin time determination or an ISI, and may be carried out with the patient sample and a coagulation reagent, where the coagulation reagent may be selected from a number of coagulation reagents. One embodiment provides an INRs value which is determined from a prothrombin time (PT or T1) of a patient blood sample and a theoretical end of test time (TEOT), where a theoretical clotting area is used to determine the INRs value according to the expression, INRs=T1*TEOT*MUL, where MUL is a multiplier that takes into account pixel parity and sampling times. The INRs may be used to determine a course of treatment for a patient or other living being without regard to the specific coagulation regent used to generate the coagulation data (e.g., time and optical activity values).

The present invention provides process of extracting thrombase from animal blood or human blood. The process includes adsorbing thrombin from plasma with chromatographic medium, eluting the chromatographic column, activating thrombin to obtain thrombase solution, ultrafiltering to concentrate and finally freeze drying to obtain the thrombase product. The process is one normal temperature process, environment friendly, short in production period, high in thrombase extracting rate of 50000 IU / L, simple in operation, and easy in industrial realization.

One kind blood samples detection method using magnetic beads, completed with the following steps: (1) Get fresh clinical samples; (2)Put these specimen on coagulation analyzer, use magnetic beads and special adjustment reagents aiming at the whole blood specimens, measure four coagulations: Activated partial thromboplastin time (APTT), Prothrombin time (PT), Prothrombin time (TT), Fibrinogen (FIB). The advantages of this invention are: 1.The method is simple, time-saving and easy to technical staff. 2. Reduce costs and save centrifuges and other equipment, reduce errors; 3. It is efficient and suitable for the battlefield, natural disasters and remote mountainous areas, medical teams. Particularly, it's suitable for hemorrhagic diseases and natural disasters (such as hemophilia, etc.). 4. Save specimen volume. 5. Reflect the level of specimens of blood coagulation preciously and accurately.

The invention provides a terpenoid shown by the formula I or pharmaceutically acceptable salt, ester or hydrate thereof. The invention also provides a preparation and application of the terpenoid. In the invention, a carbon-drop diterpene new compound separated from leonurus is carbon-drop labdane diterpene obtained from the nature for the first time. The compound can obviously shorten the PT (prothrombin time), APTT (activated partial thromboplastin time) and TT (thrombin time) in vitro and obviously increase the amount of FIB (fibrinogen) in blood, and realizes a certain effect on enhancing the coagulation function, thereby providing a new option for developing a novel natural coagulation drug.

The thrombase separating and purifying process includes: adding sodium citrate solution as anticoagulant into animal blood as material; centrifugally separating to obtain plasma; freezing, defreezing and re-centrifuging to obtain supernatant; adding BaCl2 into supernatant, centrifuging and collecting precipitate; adding EDTA solution into precipitate to desorb, and centrifuging to eliminate precipitate and obtain coarse thrombin solution; adding CaCl2 solution to the coarse thrombin solution to make the coarse thrombin solution reach a concentration of 0.1 mol / L, chromatographic separation in DEAE-cellulose anionic exchange column to obtain pure thrombase product; and freeze drying to obtain the thrombase product. The present invention has high thrombase yield of 0.4 % and high thrombase purity, specific activity of 1500 U / mg protein.

What is described is a kit for preparing a liquid thromboplastin reagent for a prothrombin time assay. The kit simplifies and minimizes reagent preparation time and is stable for 2-5 years.

The invention discloses an electrochemical detection chip. The electrochemical detection chip comprises an electrode layer, wherein a working electrode of the electrode layer comprises a conducting layer, a nanomaterial layer and a blood clotting reaction layer which are sequentially laminated, wherein the blood clotting reaction layer is used for producing an electrical signal for detecting prothrombin time; the nanomaterial layer is used for transferring and amplifying the electrical signal. By using high conductivity, large specific area, good biocompatibility and the like of the nanomaterial layer, amplification and enhancement of the electrical signal in the detection process of the prothrombin time are realized so as to improve the sensitivity of chip detection and shorten the detection time. The invention discloses an electrochemical sensor. The electrochemical sensor comprises the electrochemical detection chip. The invention discloses a preparation method of the electrochemical sensor. The preparation method is suitable for preparing the electrochemical sensor with high sensitivity and accurate detection results.

A method of determining prothrombin time (PT) in a whole blood, anti-coagulated blood, blood plasma or anti-coagulated blood plasma sample at an ambient temperature in the range of 15° C. to 45° C. is described. The method is performed with liquid reagents and the PT, preferably expressed as International Normalized Ratio (INR), is calculated based on said temperature and the clotting time (CT). A test kit is also described for analysis of PT which comprises temperature recoding means, and one or several separate sealed vessels containing reagents, optionally in lyophilized form for reconstitution prior to use, for clotting one or more defined volumes of whole blood, anti-coagulated blood, blood plasma or anti-coagulated blood plasma sample, and optionally time registration means and volume determining means.

The invention relates to a preparation method for prothrombin time determination reagent (PT reagent), comprising the following steps. Cow or sheep tissue factor with the purity of more than 90% is prepared by the genetic engineering method, phospholipid is dispersed in phosphate buffer solution containing surfactant, and then the tissue factor and the phospholipid are mixed and sufficiently combined, and finally, C18 resin is adopted to adsorb and separate the surfactant, and the PT reagent product is obtained after freeze-drying. The preparation method is stable in technique and strong in operability, and further, the obtained PT reagent has better stability, sensitiveness and fewer impurities, and the quality can be easily ensured.

Platelet contractile force (PCF) is used as a surrogate marker of thrombin generation. PCF generation occurs concomitant with the burst of prothrombin fragment F 1+2 release. The time between assay start and PCF onset is identified as the thrombin generation time (TGT), and is used in assessing risk of bleeding, in diagnosing various disorders, and in monitoring the effects of pharmaceutical and other treatments. TGT is prolonged in clotting factor deficiencies and in the presence of direct and indirect thrombin inhibitors. TGT shortens to normal with clotting factor replacement and shortens with administration of rVIIa. TGT is short in thrombophilic states such as coronary artery disease, diabetes and thromboangiitis obliterans and prolongs toward normal with oral and intravenous anticoagulants.

The invention concerns a method for the detection of the presence and / or the severity of a liver disease in a patient comprising measuring in an isolated sample TIMP-1 (Tissue Inhibitor of Metalloproteinase I), A2M (a-2-macroglobulin), PLT (number of blood plateletes, PI (prothrombin index), optionally at least one additional parameter selected from the group consisting of urea and GGT (γ-glutamyltranspeptidase) and optionally measuring at least one additional biochemical or clinical parameter and diagnosing the presence and / or severity of a liver disease based on the presence or measured levels of these parameters. The method can be used for monitoring therapeutic treatment of liver fibrosis and staging of liver fibrosis.

The invention belongs to the technical field of blood coagulation reagent preparation, and provides a novel ellagic acid compound aiming at the characteristic that ellagic acid is difficult to dissolve in water. The novel ellagic acid compound is prepared from the ellagic acid and a solid dispersant which are mixed according to a certain proportion. The solubility of the ellagic acid is improved,the problem that the ellagic acid is prone to being precipitated is solved, and the stability of the ellagic acid in products is guaranteed. The invention also provides a method for preparing an activated partial thromboplastin time measuring reagent through the ellagic acid compound. The reagent is prepared from liposomes, the ellagic acid compound, metal ions, a stabilizer and a preservative according to a certain proportion. According to the prepared reagent, through the ellagic acid solid compound, the problem that the ellagic acid is prone to being precipitated is solved, components of the liposomes are optimized, the inter assay variation between the activated partial prothrombin reagent products is lowered, the stability of the products is good, and the quality of the activated partial prothrombin reagent is guaranteed.

The invention discloses a method for simultaneously separating and purifying coagulation factors IX, X and VII from human plasma, which comprises the following steps: performing centrifugal impurity removal, gel adsorption and ultrafiltration concentration to prepare a prothrombin compound; separating the coagulation factors VII and a mixed solution containing IX and II through an anion exchange resin column; separating the coagulation factor II and IX from the mixed solution containing IX and II by affinity chromatography. According to the method, by combining anion exchange chromatography with heparin affinity chromatography, the separation and preparation of three coagulation factors II, VII and IX at the same time can be achieved; the method has the advantages of high raw material utilization, simple operation and short time consumption; meanwhile, by detecting the electric signals in the chromatography process, the corresponding coagulation factors are accurately collected, the purity of the coagulation factors is effectively improved, and the economic benefit is improved.

The invention provides a process for purifying a prothrombin compound. The process comprises the following steps: subjecting qualified detected plasma of a healthy person to centrifugation for removal of sediments so as to a raw plasma material; subjecting the raw plasma material to adsorption with DEAE-Sephadex A-50 gel and carrying out washing and elution so as to obtain crude extract of the prothrombin compound; and subjecting the crude extract of the prothrombin compound to further adsorption by using Capto DEAE gel column chromatography and carrying out washing and elution so as to obtain the liquid prothrombin compound. According to the invention, the prothrombin compound is prepared through two-step operations via the DEAE-Sephadex A-50 gel and Capto DEAE gel; and under the designed process conditions, the prepared prothrombin compound has a purity far higher than the purity of a prothrombin compound product prepared by using a traditional process, and blood coagulation factors II, IX and X are good in equalization.

The invention discloses a method for establishing a liver cancer diagnosis model based on liver cancer triple detection. The method comprises the following steps of: 1, establishing a primary hepatocellular carcinoma database of primary hepatocellular carcinoma clinical characterization and laboratory data, and collecting laboratory indexes of a patient; and 2, arranging laboratory indexes, and establishing a multi-factor Logistic regression model to obtain a liver cancer diagnosis model. The laboratory indexes of the liver cancer diagnosis model CGALAD comprise the basic information gender and age of a patient, and liver cancer serological marker alpha fetoprotein heteroplasmon, alpha fetoprotein and abnormal prothrombin. Laboratory indexes of the liver cancer diagnosis model LAD compriseliver cancer serological marker alpha fetoprotein heteroplasmon, alpha fetoprotein and abnormal prothrombin. Parameters of the two liver cancer diagnosis models are easy to obtain, the parameters areon the same inspection subdisciplinary detection platform, a single report unit is few, influence factors are few, so that the clinical applicability and feasibility of the method are high.

The invention discloses an oral caring composition which comprises asiatic centella triterpenoids and an orally acceptable carrier, wherein the triterpenoids comprise one of or a combination of more of asiaticoside, asiaticoside degradation products, hydroxy asiaticoside and hydroxyl asiaticoside degradation products. The invention further discloses application of the asiatic centella triterpenoids in inhibiting gum bleeding. Four blood coagulation indexes of the oral caring composition disclosed by the invention meet standards that the prothrombin time (PT) is less than or equal to 14.5 seconds, the thrombin time (TT) is less than or equal to 42.5 seconds, the activated part thromboplastin time (APTT) is less than or equal to 27.0 seconds, and the platelet aggregation rate is greater thanor equal to 53.5. The problem of gum bleeding can be effectively solved.

The invention provides a thromboplastin reagent comprising: tissue factor, a phospholipid and a polyphosphate that acts as a blocker of tissue factor pathway inhibitor (TFPI). Also provided are a composition for promoting clotting comprising polyphosphate, and a reagent for a clotting assay also comprising polyphosphate together with an activator of clotting. Methods for stopping or slowing wound bleeding and fibrinolysis using compositions comprising polyphosphate are also disclosed.

The invention is a fibrin glue that avoids the use of fibrinogen and thus eliminates the need for premixing and premature clot formation. The fibrin glue of the invention comprises thrombin, thromboplastin and calcium and may have clotting Factors, VII, IX and X, and the like. The invention also comprises a biosealant for use with the fibrin glue without fibrinogen or for use alone. The biosealant is a two component mixture of gelatin / resorcinol and glyoxal / glutaraldehyde / 4-(p-maleimidophenyl) butyric acid. The two components are mixed on use.

The invention relates to a bacterium resisting anticoagulant ventriculoperitoneal branch pipe silicone pipe body and a preparation method and application thereof. The branch pipe silicone pipe body isprepared from an A component and a B component in the weight ratio of 1:(0.7-1.3), wherein the A component comprises the following components in parts by weight of 100-120 parts of vinyl-containing dimethyl silicone, 0.05-10 parts of barium sulfate, 0.05-15 parts of an antibacterial agent, 0.05-15 parts of an anticoagulant and 0.5-15 parts of a dispersing agent, and the B component comprises thefollowing components in parts by weight of 70-130 parts of active hydrogen and platinum gold catalyst containing dimethyl silicone. Through extruding, curing and shaping, the bacterium resisting anticoagulant ventriculoperitoneal branch pipe silicone pipe body is obtained. The material has permanent bacterium resistance, has good bacterium resistance and long recalcification time, time for activating part of blood coagulation live enzymes, and prothrombin time.

The invention belongs to the technical field of immunodetection, and discloses a combined detection kit based on four liver cancer tumor markers: aldoketoreductase 1B10 (AKR1B10), abnormal prothrombin (DCP), alpha fetoprotein (AFP) and alpha fetoprotein variant (AFP-L3). The kit comprises: streptavidin magnetic beads; labeling AKR1B10, DCP (dicumyl peroxide) and AFP antibodies with biotin; labeling AKR1B10, DCP and AFP antibodies with acridinium ester; an LCA magnetic bead, a cleaning solution and an eluent; and AKR1B10, DCP and AFP calibration products and quality control products. By simultaneously detecting the contents of four tumor markers in serum of a subject, the risk of potential development of liver cancer of the subject is analyzed and judged. According to the invention, the sensitivity and specificity of early diagnosis of liver cancer are improved by combined detection of four tumor markers, and a more reliable basis is provided for clinical diagnosis of liver cancer.

The invention provides a multi-protein combined biomarker, application and a heart valvular disease complicated with atrial fibrillation diagnostic kit. The multi-protein combined biomarker is composed of an apolipoprotein A1 protein antibody, an angiotensin antigen antibody, an LIM structural domain protein 7, a macrophage colony stimulating factor receptor 1, a vitronectin antibody and a prothrombin fragment F1 + 2 antibody. Modern biological technology and bioinformatics analysis find that combined application of the six proteins has the application of predicting valvular heart disease complicated with atrial fibrillation, can be applied to preparation of targeted drugs for early intervention of related diseases, and can also be applied to preparation of a heart valvular disease complicated with atrial fibrillation screening kit. According to the kit, modeling is carried out after the concentrations of the six proteins are measured, and good evaluation efficiency and potential hugeapplication value are achieved on whether atrial fibrillation happens to a patient suffering from the heart valvular disease or not.

The invention discloses a system and a method for testing the possibility that a subject suffers from liver cancer. The system comprises a data acquisition module for acquiring data of gender, age, abnormal prothrombin (DCP) and alpha fetoprotein (AFP) of a subject; and the data processing module is used for processing the data acquired in the data acquisition module, including respectively taking logarithmic functions for the DCP data and the AFP data, and further respectively setting weights for the gender, the age and the DCP and the AFP after taking the logarithmic functions, thereby calculating an evaluation value P (Y). According to the system and the method, the problem that prediction of the liver cancer by a single index cannot meet clinical requirements is solved. In addition, by means of the system, the sensitivity and specificity of liver cancer screening can be remarkably improved.

The present invention relates to improved clotting compositions for producing high quality blood serum samples for analyte testing, such as for pathology testing and other biological assays. In particular, the present invention relates to the use of prothrombin activators in combination with stabilizing agents such as colloids for producing high quality blood serum samples. The present invention also relates to associated methods for preparing clotting compositions, tubes, kits and methods of diagnosis, prognosis and monitoring for responsiveness to therapy.

The invention discloses a prothrombin time detection test strip and a preparation method thereof. The test strip comprises a hydrophilic layer, a diffusion layer arranged below the hydrophilic layer,a first bonding layer arranged between the hydrophilic layer and the diffusion layer, a red blood cell separation layer arranged below the diffusion layer, a reagent layer arranged below the red bloodcell separation layer, an electrode layer arranged below the reagent layer, a substrate arranged below the electrode layer, and a second bonding layer which fixes the reagent layer and is located between the first bonding layer and the substrate. The detection test strip is advantaged in that a single-hole single-reagent method is adopted to test the prothrombin time, the test strip can be suitable for testing samples with different hematocrit, is matched with a dry-type multifunctional analyzer for use, and is rapid in detection, and the obtained detection result has high accuracy.

The invention discloses a rapid hemostat suitable for war wound massive hemorrhage, and relates to the technical field of medical instruments; the rapid hemostat comprises an injection mechanism and ahemostatic material, wherein the injection mechanism comprises an injection cylinder, a piston, an injection cylinder front cover and a percussion assembly; the hemostatic material is composed of barium sulfate powder with a diameter of less than 2 [mu] m, chitosan particles with a high deacetylation degree (greater than 90%) and a diameter of 2 mm, and prothrombin powder. The chitosan particlesin the hemostatic material rapidly expand to press a bleeding point, prothrombin is combined to promote fibrinogen to be converted into fibrin solidified blood to achieve the purpose of rapid hemostasis; and the chitosan particles are filled with barium sulfate powder which can be developed under X-ray radiography, so that identification and thorough taking of rear hospitals are facilitated. The rapid hemostat has the advantages of being simple, safe, economical and practical, is suitable for bleeding which is not prone to compression control and is caused by trauma of a body joint area and ajunction area and damage to large blood vessels, and is exact in hemostasis effect and high in hemostasis speed.

The invention specifically discloses application of a blood index for detecting the severity of a patient infected with coronavirus, comprising the following specific steps of: S1, detecting blood indexes of the hospitalized coronavirus-infected patients, and analyzing the change condition of the blood indexes; and S2, judging the severity of the patient infected with the coronavirus according tothe change condition of the blood indexes in the step S1. The blood indexes in the invention include at least one of platelet content, blood glucose content, total cholesterol content, high density lipoprotein content, low density lipoprotein content, prothrombin time, D-dimer content, and DIC score. Therefore, the severity of the coronavirus-infected patient can be accurately judged by detectingand analyzing the change condition of the blood indexes. The invention has the characteristics of timeliness, accuracy and high efficiency, and the problem that the treatment of the coronavirus-infected patient by using a clinical phenotype has a certain hysteresis phenomenon in the prior art is effectively solved.

The invention discloses a method for simultaneously separating and purifying coagulation factors IX, X and VII from human plasma, which comprises the following steps: performing centrifugal impurity removal, gel adsorption and ultrafiltration concentration to prepare a prothrombin compound; separating the coagulation factors VII and a mixed solution containing IX and II through an anion exchange resin column; separating the coagulation factor II and IX from the mixed solution containing IX and II by affinity chromatography. According to the method, by combining anion exchange chromatography with heparin affinity chromatography, the separation and preparation of three coagulation factors II, VII and IX at the same time can be achieved; the method has the advantages of high raw material utilization, simple operation and short time consumption; meanwhile, by detecting the electric signals in the chromatography process, the corresponding coagulation factors are accurately collected, the purity of the coagulation factors is effectively improved, and the economic benefit is improved.